SOUTHWEST ONCOLOGY GROUP

西南肿瘤集团

基本信息

批准号：
2007061
负责人：
MICHAEL R GREVER
金额：
$ 31.24万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1984
资助国家：
美国
起止时间：
1984-01-01 至 1997-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/2007061
关键词：
adenocarcinoma antineoplastics azacitidine bone marrow transplantation breast neoplasms cancer prevention cis platinum compound clinical trials colony stimulating factor combination cancer therapy combination chemotherapy cooperative study cyclophosphamide dacarbazine deoxycoformycin doxorubicin drug adverse effect drug interactions etoposide fluorouracil gastrointestinal neoplasms hairy cell leukemia head /neck neoplasm hepatocellular carcinoma human subject human therapy evaluation ifosfamide immunomodulators interferon alpha interleukin 1 interleukin 2 interleukin 3 leukemia lung neoplasms lymphokine activated killer cell melanoma melphalan mesothelioma metastasis mitomycin C mitoxantrone multidrug resistance multiple myeloma nasopharyngeal neoplasms neoplasm /cancer chemotherapy neoplasm /cancer diagnosis neoplasm /cancer education neoplasm /cancer immunotherapy neoplasm /cancer radiation therapy neoplasm /cancer relapse /recurrence neoplasm /cancer surgery ovary neoplasms paclitaxel pancreas neoplasms passive immunization prognosis renal cell carcinoma sarcoma splenectomy therapy compliance tumor necrosis factor alpha urinary tract neoplasms uterus neoplasms

项目摘要

This is a multi-disciplinary collaborative research project directed toward the development of more effective methods of prevention, detection, and treatment of human cancer in all its forms. Included in this project are the following programs: 1) the exploration of new therapeutic agents through a wide range of neoplastic diseases in Phase I, II and III studies, and the coincident study of the toxicities of these agents; 2) the exploration of new combinations of new and old agents in an effort to exploit synergistic combinations more effectively; 3) the development of multi-modal approaches to specific tumor problems using surgical, immunological and radiotherapeutic measures in optimal combinations; 4) the involvement of pertinent basis science disciplines such as biochemistry, pharmacology, cellular biology and mathematics in the formulation and execution of specific treatment protocols; 5) the improvement of cancer care in the community at large by using these programs in the educational effort directed at pre- and post- doctoral students, nurses, allied medical personnel and physicians, 6) the correlation and evaluation of biologic studies, and 7) the evaluation of cancer control efforts to as early detection mechanisms. This research effort will be conducted in cooperation with clinical and basic science investigators at other SWOG institutions and the NCI whose collective experience, information and wisdom will be used to design and conduct clinical trials which will answer important questions in the therapy of cancer. The Ohio State University has been a member and active participant in the Southwest Oncology Group for over thirty years. During this period OSU has grown to be the leading contributor in patient accrual for all SWOG institutions.

这是一个多学科的合作研究项目为了开发更有效的预防方法，以所有形式的人类癌症检测和治疗。包括在该项目是以下程序：1）探索新的通过各种肿瘤疾病的治疗剂 I，II和III研究，以及关于毒性的一致研究这些代理商； 2）探索新老式的新组合代理，以更有效地利用协同组合； 3）开发特定肿瘤问题的多模式方法在最佳中使用手术，免疫学和放射治疗措施组合； 4）相关基础科学学科的参与例如生物化学，药理学，细胞生物学和数学特定治疗方案的制定和执行； 5）通过使用这些来改善社区的癌症护理针对博士前和博士后的教育工作中的课程学生，护士，盟军医务人员和医生，6）生物学研究的相关性和评估，以及7）评估癌症控制工作以作为早期检测机制。这项研究将与临床和基础科学合作进行努力其他Swog机构和NCI的调查人员的集体经验，信息和智慧将用于设计和进行临床试验将在治疗中回答重要问题癌症。俄亥俄州立大学一直是成员和积极参与者西南肿瘤学集团已有30多年了。在此期间OSU 已经成为所有摇摆的患者应计的主要贡献者机构。

项目成果

期刊论文数量（66）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Phase II investigation of pentostatin in multiple myeloma: a Southwest Oncology Group study.

喷司他丁治疗多发性骨髓瘤的 II 期研究：西南肿瘤小组研究。

DOI：
10.1093/jnci/82.22.1778
发表时间：
1990
期刊：
Journal of the National Cancer Institute
影响因子：
0
作者：
Grever,MR;Crowley,J;Salmon,S;McGee,R;Kraut,EH;Buys,SS;Rivkin,SE
通讯作者：
Rivkin,SE

Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stage III, optimal disease ovarian cancer: a Southwest Oncology Group Study.

对先前未经治疗的 III 期最佳疾病卵巢癌患者进行化学免疫治疗的随机 III 期试验：西南肿瘤学小组研究。

DOI：
10.1016/0090-8258(89)90842-1
发表时间：
1989
期刊：
Gynecologic oncology
影响因子：
4.7
作者：
Alberts,DS;Mason-Liddil,N;O'Toole,RV;Abbott,TM;Kronmal,R;Hilgers,RD;Surwit,EA;Eyre,HJ;Baker,LH
通讯作者：
Baker,LH

Phase II evaluation of teniposide and ifosfamide in refractory adult acute lymphocytic leukemia: a Southwest Oncology Group Study.

替尼泊苷和异环磷酰胺治疗难治性成人急性淋巴细胞白血病的 II 期评估：西南肿瘤小组研究。